Propentofylline: Difference between revisions
No edit summary |
No edit summary |
||
Line 41: | Line 41: | ||
| molecular_weight = 306.360 g/mol | | molecular_weight = 306.360 g/mol | ||
}} | }} | ||
__NOTOC__ | |||
{{SI}} | |||
{{CMG}} | |||
==Overview== | |||
'''Propentofylline''' ('''HWA 285''') is a [[xanthine]] derivative with purported [[neuroprotective]] effects. | '''Propentofylline''' ('''HWA 285''') is a [[xanthine]] derivative with purported [[neuroprotective]] effects. | ||
Revision as of 13:04, 13 April 2015
Clinical data | |
---|---|
AHFS/Drugs.com | International Drug Names |
ATC code | |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
UNII | |
E number | {{#property:P628}} |
ECHA InfoCard | {{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value). |
Chemical and physical data | |
Formula | C15H22N4O3 |
Molar mass | 306.360 g/mol |
(verify) |
WikiDoc Resources for Propentofylline |
Articles |
---|
Most recent articles on Propentofylline Most cited articles on Propentofylline |
Media |
Powerpoint slides on Propentofylline |
Evidence Based Medicine |
Clinical Trials |
Ongoing Trials on Propentofylline at Clinical Trials.gov Trial results on Propentofylline Clinical Trials on Propentofylline at Google
|
Guidelines / Policies / Govt |
US National Guidelines Clearinghouse on Propentofylline NICE Guidance on Propentofylline
|
Books |
News |
Commentary |
Definitions |
Patient Resources / Community |
Patient resources on Propentofylline Discussion groups on Propentofylline Patient Handouts on Propentofylline Directions to Hospitals Treating Propentofylline Risk calculators and risk factors for Propentofylline
|
Healthcare Provider Resources |
Causes & Risk Factors for Propentofylline |
Continuing Medical Education (CME) |
International |
|
Business |
Experimental / Informatics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Propentofylline (HWA 285) is a xanthine derivative with purported neuroprotective effects.
Pharmacology
It is a phosphodiesterase inhibitor.[1]
It also acts as an adenosine reuptake inhibitor.[1][2][3]
Uses
It was studied as a possible treatment for Alzheimer's disease and multi-infarct dementia.[4][5]
Propentofylline has also been studied, to a lesser extent, as a possible adjunct in the treatment of ischemic stroke, due to its vasodilating properties.[6][7]
Propentofylline is in use in veterinary medicine as a geriatric preparation for old dogs.
See also
References
- ↑ 1.0 1.1 Frampton M, Harvey RJ, Kirchner V (2003). Frampton, Maria A, ed. "Propentofylline for dementia". Cochrane Database Syst Rev (2): CD002853. doi:10.1002/14651858.CD002853. PMID 12804440.
- ↑ Salimi S; Fotouhi A; Ghoreishi A; et al. (April 2008). "A placebo controlled study of the propentofylline added to risperidone in chronic schizophrenia". Prog. Neuropsychopharmacol. Biol. Psychiatry. 32 (3): 726–732. doi:10.1016/j.pnpbp.2007.11.021. PMID 18096287. Unknown parameter
|author-separator=
ignored (help) - ↑ Numagami Y, Marro PJ, Mishra OP, Delivoria-Papadopoulos M (June 1998). "Effect of propentofylline on free radical generation during cerebral hypoxia in the newborn piglet". Neuroscience. 84 (4): 1127–1133. doi:10.1016/S0306-4522(97)00542-3. PMID 9578400.
- ↑ Frampton M, Harvey RJ, Kirchner V (2003). Frampton, Maria A, ed. "Propentofylline for dementia". Cochrane database of systematic reviews (Online) (2): CD002853. doi:10.1002/14651858.CD002853. PMID 12804440.
- ↑ Kittner B, Rössner M, Rother M (1997). "Clinical trials in dementia with propentofylline". Ann. N. Y. Acad. Sci. 826: 307–316. doi:10.1111/j.1749-6632.1997.tb48481.x. PMID 9329701.
- ↑ Bath PM, Bath-Hextall FJ (2004). Bath, Philip MW, ed. "Pentoxifylline, propentofylline and pentifylline for acute ischaemic stroke". Cochrane database of systematic reviews (Online) (3): CD000162. doi:10.1002/14651858.CD000162.pub2. PMID 15266424.
- ↑ Huber M, Kittner B, Hojer C, Fink GR, Neveling M, Heiss WD (1993). "Effect of propentofylline on regional cerebral glucose metabolism in acute ischemic stroke". J. Cereb. Blood Flow Metab. 13 (3): 526–30. doi:10.1038/jcbfm.1993.68. PMID 8478410.
- Pages with script errors
- Pages with reference errors
- CS1 maint: Multiple names: authors list
- Pages with citations using unsupported parameters
- Template:drugs.com link with non-standard subpage
- E number from Wikidata
- ECHA InfoCard ID from Wikidata
- Articles without EBI source
- Chemical pages without ChemSpiderID
- Chemical pages without DrugBank identifier
- Articles without KEGG source
- Articles without InChI source
- Drugs with no legal status
- Drugboxes which contain changes to watched fields
- Xanthines
- Vasodilators
- Cardiovascular Drugs
- Drug